Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

0.8117
+0.00911.13%
Post-market: 0.82000.0083+1.02%19:55 EDT
Volume:783.63K
Turnover:598.06K
Market Cap:13.43M
PE:-0.18
High:0.8872
Open:0.7900
Low:0.7583
Close:0.8026
52wk High:12.23
52wk Low:0.7583
Shares:16.54M
Float Shares:11.46M
Volume Ratio:3.33
T/O Rate:6.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5617
EPS(LYR):-19.4955
ROE:-931.14%
ROA:-79.37%
PB:-12.32
PE(LYR):-0.04

Loading ...

Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 15

Tempest Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
May 08

Tempest says TPST-2003 dual-target CAR-T hits 100% complete response in Phase 1 trials

Reuters
·
May 06

Jakarta, Danantara Sign Rp17.4 Trillion Waste-to-Energy Deal

Tempo
·
May 05

Tempest to present TPST-2003 clinical update at ISCT annual meeting

Reuters
·
Apr 29

Tempest Therapeutics provides update on development of TPST-2003

TIPRANKS
·
Apr 22

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

GlobeNewswire
·
Apr 22

Press Release: Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Dow Jones
·
Apr 14

Tempest Therapeutics Inc - Company Will Not Receive Proceeds From Sale of Shares by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Apr 02

Tempest Therapeutics Inc - Prospectus Filed for Resale of up to About 2.8 Mln Shares Including Warrants - SEC Filing

THOMSON REUTERS
·
Apr 02

Tempest Therapeutics files to sell 2.78M shares of common stock for holders

TIPRANKS
·
Apr 02

Tempest Therapeutics files to sell 8.27M shares of common stock for holders

TIPRANKS
·
Mar 31

Tempest Therapeutics Inc - Offers up to 8.27 Mln Shares of Common Stock for Resale by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Mar 31

BRIEF-Tempest Reports Year End 2025 Financial Results And Provides Business Update

Reuters
·
Mar 30

Tempest Therapeutics Inc - Appoints Matt Angel as CEO and President

THOMSON REUTERS
·
Mar 30

Tempest Therapeutics Inc - Reports Net Loss of $26.3 Mln and Net Loss per Share of $6.33 for 2025

THOMSON REUTERS
·
Mar 30

Tempest Therapeutics Inc - Announces Positive Interim Data From Redeem-1 Phase 1/2a Trial of Tpst-2003

THOMSON REUTERS
·
Mar 30

Press Release: Tempest Reports Year End 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 30

Tempest FY25 net loss narrows to $26.3 million; cash drops to $7.7 million

Reuters
·
Mar 30

Tempest Therapeutics CEO and President Matthew Angel acquires 231,482 common shares; value rises to $500,001

Reuters
·
Mar 26